CALL FOR VIGILANCE: SYPHILIS

Draft by the infectious-diseases team based on INSPQ, INESSS and MSSS communications Nunavik Dept. of Public Health

CONTEXT

- Nunavik is a region at elevated risk of STBIs, including chlamydiosis and gonorrhea.
- In Nunavik, one case of syphilis was reported to the DPH in 2013 and another has just been confirmed.
- Since 2012, Nunavut has seen outbreaks of syphilis. Our Cree neighbours also saw aggregate cases in 2013.
- In Québec, a resurgence of infectious syphilis has been observed since the early 2000s, first among MSM (men who have sex with men), followed by an increase in the number of cases among young persons aged 15 to 24 years (with no link to MSM), including women of childbearing age, with the risk of onset of related congenital syphilis.
- Syphilis is not easy to diagnose due to multiform clinical manifestations. Sometimes it can even remain asymptomatic in the primary, secondary and latent stages. Untreated, it can be communicable for one year and be linked to higher rates of morbidity and mortality (tertiary or congenital syphilis).
- Syphilis-related lesions increase the risk of HIV infection by two to five times.
- Syphilis is a disease reportable by physicians and laboratories.

Transmission

- Vaginal, anal or oro-genital sexual contact, with or without penetration: highest risk.
- Transplacental transmission from infected mother to foetus.
- Direct contact with exudate from skin or mucosal lesions.
- Indirect contact (e.g., sexual toys).
- Less-frequent methods of transmission:
  - blood transfusion when transfusion safety measures are not applied (e.g., in certain foreign countries).
  - sharing of injection materials.

Syphilis is deemed infectious when the contagion is highest, i.e., during the primary, secondary and early-latent stages. These stages correspond to the first year of the disease.

Screening: regional recommendations for asymptomatic individuals

Besides laboratory tests for diagnostic purposes among all individuals with signs or symptoms compatible with syphilis, screening for syphilis should be performed among:

- all pregnant women at the first visit for pregnancy, at 28 weeks (at the same time as repeat screening for gonorrhea and chlamydiosis) and at 36 weeks (or at time of delivery if not performed at 36 weeks).
- all asymptomatic individuals with risk factors
  - See factsheet on Screening according to Risk Factors, used in Nunavik clinics for follow-up to consultations related to sexual health and STBIs. Consult the guide: Nunavik Sexual Health and STBIs, January 2015, section 1.
- partners
  a. All partners of an individual with confirmed syphilis should be tested according to the period of contagiosity, through a clinical and serological examination (request Serology for syphilis).
     If negative, the test should be repeated three months later, to take into account the window period (10 days to three months): average of three weeks post infection, unless the last sexual relations date back more than three months from the initial test.
  b. All pregnant partners of a confirmed case must be reported.
c. Epidemiological treatment, i.e., without waiting for serology results, is recommended for all contacts of a confirmed case or a case with classic primary (chancre) or secondary lesions supported by an epidemiological context.

Clinical manifestations and infectious period
For the stages of the disease and their most-common clinical manifestations, consult:

Laboratory test
Refer to the INSPQ document Mise à jour des algorithmes de sérodiagnostic de la syphilis : avis scientifique, Québec, INSPQ, 2016. (French version only)

Treatment
Refer to the MSSS document Mise à jour Mars 2016. Traitemnt pharmacologique ITSS. Syphilis. (French version only)

In brief
- The first choice is penicillin G benzathine (Bicillin L-A), 2.4 million IU, long-acting penicillin.
- The number of required treatments and the type of antibiotics used depend on the stage of syphilis, as well as other factors (e.g., HIV status, allergy to penicillin, pregnancy and breast-feeding, etc.). It is therefore recommended to consult an infectiologist before treating any case of syphilis.
- Serological follow-up with a quantitative RPR test is required to evaluate the reaction to treatment 3, 6 and 12 months after administration thereof.

Physicians of the Nunavik DPH and Designated Infectiologists of the MUHC
The physicians below can reply to queries on sexually transmitted infections. Outside normal office hours, refer to the List of physicians on duty for the Nunavik DPH.

Dr. Jean-François Proulx
Medical Advisor for Infectious Diseases
Tel.: 418 666-7000, #482
Cell.: 418 933-2191
Confidential fax: 1 866 867-8026
E-mail: jean-francois.proulx.ciussscn@ssss.gouv.qc.ca

Dr. Mario Brisson
Medical Advisor for Infectious Diseases and Environmental Health
Tel.: 418 666-7000, #335
Cell.: 418 580-5034
Confidential fax: 1 866 867-8026
E-mail: mario_brisson@ssss.gouv.qc.ca

Dr. Véronique Morin (as of June 2017)
Médecin-conseil en santé sexuelle
Télec. confidentiel : 1 866 867-8026
E-mail: veronique.morin@ssss.gouv.qc.ca

Dr. Michael Libman
Designated Infectiologist, MUHC
Tel.: 514 934-1934, #53333
E-mail: michael.libman@muhc.mcgill.ca
Schedule: Mon. to Fri., 8:00 a.m. to 4:00 p.m.
Infectiologist on duty weekends

Dr. Dr. Cédric Yansouni
Infectiologist, MUHC
Tel.: 514 934-1934, #76173
E-mail: cedric.yansouni@muhc.mcgill.ca

Resources for Information and Counselling for Clients
Faye Le Gresley
Nurse, Sexual Health Program
Nunavik Dept. of Public Health
Tel.: 819 964-2222 / 1 844 964-2244, #269
Confidential fax: 1 866 867-8026
E-mail: faye.legresley@ssss.gouv.qc.ca

- Consult Nunavut sexual-health Website: http://www.irespectmyself.ca/
- CATIE (Canada’s source for HIV and hepatitis C information): www.catie.ca